Omega Therapeutics announces collaboration with Stanford University School of Medicine

Article

The development-stage biotechnology company Omega Therapeutics is teaming up with Stanford University to investigate therapies for ocular diseases via control of specific ocular disease genes.

Omega Therapeutics announces collaboration with Stanford University School of Medicine

On October 14, Omega Therapeutics announced a strategic research collaboration with investigators at the Stanford University School of Medicine to examine the prospect of Omega Epigenomic Controllers (OECs) as a therapy to control ocular disease genes associated with inflammation or regeneration of ocular tissues. Together, the institutions will use the OMEGA Epigenomic Programming platform to examine novel ocular targets for potential candidates for OEC development.

The project involves the members of Omega and the ophthalmology department of Stanford University School of Medicine. Albert Wu, MD, PhD, FACS, Associate Professor of Ophthalmology, has been named principal investigator, and additional contributors will include Jeffrey Goldberg, MD, PhD, Professor and Chair of Ophthalmology, and Michael Kapiloff, MD, PhD, Associate Professor (Research) of Ophthalmology.

"Through this research collaboration, we aim to expand the reach of our OMEGA platform within regenerative medicine, immunology, and inflammation with ocular disease targets," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "We will continue exploration of the broad potential of our disruptive platform and OECs, our new class of mRNA therapeutics as programmable epigenetic medicines."

About Omega Therapeutics

Founded in 2017, Omega Therapeutics is a development-stage biotechnology company developing the first systematic approach for mRNA therapeutics as programmable epigenetic medicines. The OMEGA Epigenomic Programming™ platform utilizes the power of epigenetics, which control gene expression and every step of an organism’s lifespan, from genesis to cell death. By mobilizing the fundamental epigenetic processes, the OMEGA platform corrects the root cause of disease by corrected aberrant gene expression without changing native nucleic acid sequences.

Omega’s development candidates in the pipeline reach across ranges of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visit omegatherapeutics.com.

Related Content: Ophthalmology | Retinal Surgery | Imaging

Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.